Avoiding the Billion Dollar Delay:

BioPharma Challenges in Planning and Utilization of Infrastructure, Operations and Resources

14 September 2021   |    11:00 AM – 12:00 PM EDT

Increasing competition, the need to accelerate time-to-market for therapeutics, and new ways of working is forcing the biopharmaceutical industry to rethink how and where to conduct research. Traditionally, the industry has built customized “mono-purpose” labs with long lead times and significant capital expenditures, which makes it difficult to pivot or adapt to unanticipated changes in R&D demands, shifts or delays in the pipeline, drug failures, the impact of M&A, and unexpected opportunities.

 

This Virtual Roundtable will examine the challenges and costs BioPharma faces when pivoting to the unexpected and the specific role that infrastructure can play in providing solutions.

Questions to be discussed include:

  • How does pharma plan out the R&D workflow for future infrastructure?
  • What are the factors that may cause unexpected changes to occur? How does infrastructure impact or limit responding to these changes?
  • What are the economic impacts and delays that can result from infrastructure related challenges?
  • What strategies does pharma employ to mitigate the challenge of unexpected shifts?
  • How does outsourcing to CRO’s/CDMO’s support pharma in responding to the unexpected? What challenges does this strategy present?
  • What strategies or solutions is pharma developing to allow the requisite flexibility to change R&D workflows and better respond to changes in priorities?

Sponsored by:

SmartLabs is accelerating the pace of scientific discovery by radically transforming the way the world builds and uses lab space.  Where lab construction can take 9 to 12 months in the traditional process, we deliver customized and effective lab workflow environments in about 4 weeks.  This huge reduction in time means member teams are starting sooner and results are delivered faster. We continue to compound these time savings with our proactive operational support and ability to pivot and change lab space quickly as member science evolves and lab needs change.  We currently have locations in the MIT area of Cambridge, at Innovation Square in the Boston Seaport, in Boston Landing, and a new development in South San Francisco. We are excited to participate in the roundtable to learn how the flexible lab infrastructure from SmartLabs can transform Pharma R&D

https://www.smartlabs.com/